Reports Q4 revenue $3.24B, consensus $3.24B. "Our global team continues living our mission to transform lives, and I’m proud of the results we achieved in the fourth quarter and throughout 2022," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "In the year ahead we remain committed to our goals of delivering new, meaningful innovations to benefit patients globally while continuing to deliver differentiated financial performance."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BSX:
- BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022
- Notable companies reporting before tomorrow’s open
- Citi Says Market Upside Appears Limited, but These 2 Stocks Have More Room to Run
- Boston Scientific put volume heavy and directionally bearish
- Boston Scientific targeting ‘double digit’ EPS growth in 2023, consensus $1.93
